___

• Pak YC. Etiology and treatment of urolithiasis. Amer J Kidney Disease 1991; 18 (6): 624-37.
• Pak YC. Role of medical prevention. J Urol 1989; 141: 798–801.
• Asplin J, Parks J, Lingeman J, Kahnoski R, Mardis H, Lacey S, Goldfarb D, Grasso M, Coe F. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol 1998; 159: 1821–5.
• Finlayson B. Physicochemical aspects of urolithiasis. Kidney Int 1978; 13: 344–9.
• Kok DJ, Papapoulos SE. Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis. Bone Miner 1993; 20: 1–6.
• Pak YC, Fuller C, Sakhaee K, Preminger MG, Britton F. Long – term treatment of calcium nephrolithiasis with potassium citrate. J Urol 1985; 134: 11–9.
• Parks HJ, Coe LF. The financial effects of kidney stone prevention. Kidney Int 1996; 50: 1706–12.
• Nicar MJ, Hsu MC, Johnson T, Pak YC. The preservation of urine samples for determination of renal stone risk factor. 1987; 18 ( 6 ): 382–4.
• Pak YC, Skurla C, Harvey J. Graphic display of urinary risk factors for renal stone formation. J Urol 1989; 134: –870.
• Laube N, Schneider A, Hesse A. A new approach to calculate the risk of calcium oxalate crystallization from unprepared native urine. Urol Res 2000; 28: 274–80.
• Robertson WG. Pathophysiology of stone formation. Urol Int 1986; 41: 329–33.
• Robertson WG, Peacock M. Pathogenesis of urolithiasis in Scheneider. Handbook of Urology 1985; 17 (1): –334.
• Bongartz D, Scheneider A, Hesse A. Direct measurement of calcium oxalate nucleation with laser probe. Urol Res 1999; 27: 135–40.
• Brondus AE, Isogno KL, Lang R, Ellison AF, Dreyer BE. Evidence for disordered control of 1 – 25 dihydroxyvit- amine D production in absorptive hypercalciuria. N Engl J Med 1984; 11: 73–9.
• Hess B, Meinhardt U, Zipperle L, Giovanoli R. Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. Urol Res 1995; 23: 231–8.
• Nicar MJ, Skurla C, Sakhaee K, Pak YC. Low urinary citrate excretion in nephrolithiasis. Urology 1983; 21: –12.
• Nicar MJ, Hill K, Pak YC. Inhibition by citrate of spontaneous precipitation of calcium oxalate in vitro. J Bone Min Res 1987; 2: 215–8.
• Pak YC. Citrate and Renal Calculi. Miner Electrolyte Metab 1994; 20: 371–7.
• Tisellius HG. The effect of the pH on the risk of calcium oxalate crystallization in urine. Eur Urol 1986; 12: –61.
• Riese RJ, Sakhaee K. Uric acid nephrolithiasis: pathogenesis and treatment. J Urol 1992; 148: 765–71.
• Gutman BA, Tsai – Fan Y. Uric acid nephrolithiasis. J Amer Med 1968; 45: 756–75.
• De Vries A. Purine metabolism in uric acid lithiasis. Scan J Urol Nephrol 1980; 53: 161–70.
• Hodgkinson A, Zarembski PM. Oxalic acid metabolism in man. Calcified Tissue Res 1968; 2: 115–24.
• Hagler L, Herman RH. Oxalate metabolism. Amer J Clin Nutr 1973; 26: 758–65.
• Schmidt KH, Hagmaier V, Hornig DH, Vuilleumier JP, Rutishauser G. Urinary oxalate excretion after intakes of ascorbic acid in man. Amer J Clin Nutr 1981; 34: 305–9.
• Grases F, Genaster C, Conte A, March P, Bouza C. Inhibitory effect of pyrophosphate, citrate, magnesium and chondroitin sulphate in calcium oxalate urolithiasis. Br Journal Urol 1989; 64: 235–7.